International Brand Name:
Endoxan , Cytoxan, Neosar , Procytox
In treatment of:
CONDITIONING REGIMEN FOR BONE MARROW TRANSPLANTATION
8. Hemorrhagic cystitis
12. Pulmonary fibrosis
13. Reversible alopecia
15. Secondary malignant disease
17. Darkening of the skin and nails.
18. Facial flushing
20. Runny eyes and nose
1. Hypersensitivity to this drug
2. Bone marrow suppression
1. Impaired renal function
2. Hepatic failure
5. Dependant on chemotherapy and radiation therapy
Chloramphenicol: Decreased efficacy of cyclophosphamide due to increase in half-life and decrease in metabolite concentration, increased risk of bone marrow toxicity.
Thiazide diuretics: Increased efficacy, anti-neoplastic induced leukopoenia may be prolonged.
Anticoagulants: Increase in anticoagulant effect.
Digoxin: Decreased serum levels of digoxin.
Doxorubicin: Doxorubicin induced cardiac toxicity potentiated.
Succinylcholine: Neuromuscular blockade prolonged.
Allopurinol: Increased risk of bone marrow toxicity.
Phenobarbitone: Increased metabolism and leukopenic activity.
Myelotoxic drugs, Radiotherapy: Serious toxicity.
Adults - 60mg/kg daily for 2 to 4 days.
Adults-2 to 6 mg/kg weekly as a single low-dose regimen.
10 to 15 mg/kg weekly as a single moderate-dose regimen.
20 to 40 mg/kg as a single high- dose regimen every 10 to 20 days